“…uPA, a serine protease with multiple function, acts as risk assessment and a possible treatment target in many cancers, [10,17,18] such as breast cancer, [9,19,20] pancreatic cancer, [21,22] prostate cancer, [23,24] and ovarian cancer. [25–27] In particular, uPA can accelerate tumor metastasis and promote tumor angiogenesis by degrading extracellular matrix (ECM) and basement membranes, such as vimentin and fibronectin, involving in epithelial-mesenchymal transition (EMT). [27,28] Moreover, international guidelines (AGO, St. Gallen, ASCO) recommend the use of uPA and plasminogen activator inhibitor-1 (PAI-1) expression to better assess potential clinical benefit from adjuvant systemic treatment of breast cancer.…”